Blood Brain Barrier Osmotic Disruption for Treatment of Brain Tumors

Medicare national coverage excludes osmotic blood-brain barrier disruption (BBBD) when used as part of a treatment regimen for brain tumors; this non-coverage is effective for services on or after March 20, 2007. This determination does not change Medicare coverage of anti-cancer chemotherapy, which remains governed by existing policy.

"Osmotic blood-brain barrier disruption (BBBD) used as part of a treatment regimen for brain tumors is not reasonable and necessary and is nationally non-covered for services performed on or after 2..."

Sign up to see full coverage criteria, indications, and limitations.